UPDATE 1-Regeneron quarterly profit beats on strong drug sales

Adds drug sales, analyst estimates

Feb 5 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O on Friday reported a quarterly profit that beat analysts' estimates, benefiting from a recovery in demand for its flagship eye drug and a jump in sales of its eczema drug.

Physician-administered macular degeneration drug Eylea sales were hurt during the height of the pandemic last year as patients were reluctant to visit doctors' offices.

As lockdowns eased, U.S. sales of the drug rose nearly 10% to $1.34 billion for the fourth quarter. nPn8r2BGpa

Sales from eczema drug Dupixent, which are recorded by Regeneron partner Sanofi SASY.PA, were $1.17 billion, compared to $751.5 million a year earlier.

Regeneron earned $9.53 per share on an adjusted basis, beating estimates of $8.39 per share, according to Refinitiv IBES data.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

((manojna.kalyani@thomsonreuters.com; +91 8061822700;))